Undisclosed TL1A × IL-23 BsAb
/ Shanghai Ailux Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 16, 2025
Preclinical evaluation of a TL1A × IL-23 bispecific antibody for immune-mediated inflammatory diseases
(ECCO-IBD 2026)
- "The favorable PK profile supports extended dosing intervals, a key benefit for patients with chronic IMIDs. These findings warrant further development of ALX001 for the treatment of IMIDs."
Preclinical • Inflammation • Inflammatory Bowel Disease • IL17A • IL22 • IL23A
1 to 1
Of
1
Go to page
1